title: Cost effectiveness of pharmacotherapies in early Parkinson's disease.
abstract: Parkinson's disease is one of the most common chronic neurodegenerative diseases. The progression of disease and the psychosocial consequences exert a major impact on patients' health-related quality of life. Although levodopa provides the best symptomatic benefit with the fewest short-term adverse effects, long-term treatment results in motor complications that are associated with both higher costs and considerable increase in patients' discomfort. The introduction of dopamine agonists early in the treatment of Parkinson's disease leads to a delay of these motor complications, but the treatment is associated with higher costs.In this review we evaluate available cost-effectiveness analyses of the dopamine agonists pramipexole, pergolide, bromocriptine, ropinirole, cabergoline and levodopa in the treatment of early Parkinson's disease. Considerable methodological differences in the identified studies complicate a comparison and impede clear evidence as to which dopamine agonist treatment is the most cost effective in early Parkinson's disease. Novel head-to-head comparisons considering the actual treatment guidelines are necessary to identify the most cost-effective alternative in treating de novo Parkinson's disease patients.
authors.affiliation: Department of Neurology, Philipps-University Marburg, Marburg, Germany.
authors.forename: Karla M
authors.initials: KM
authors.lastname: Eggert
authors.forename: Jens P
authors.initials: JP
authors.lastname: Reese
authors.forename: Wolfgang H
authors.initials: WH
authors.lastname: Oertel
authors.forename: Richard
authors.initials: R
authors.lastname: Dodel
mesh_terms: D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics*
chemical_list: D000978:Antiparkinson Agents
references.citation: Arch Neurol. 2002 Dec;59(12):1937-43
references.pmid: 12470183
references.citation: Eur J Health Econ. 2004 Oct;5 Suppl 1:S63-6
references.pmid: 15754076
references.citation: Mov Disord. 2007 Aug 15;22(11):1528-37
references.pmid: 17523198
references.citation: Drugs Aging. 2006;23(9):693-721
references.pmid: 17020395
references.citation: Pharmacoeconomics. 2005;23(12):1257-70
references.pmid: 16336019
references.citation: Eur J Neurol. 2005 Jun;12 Suppl 1:68-73
references.pmid: 15877783
references.citation: Med Care. 2005 Jul;43(7 Suppl):5-14
references.pmid: 16056003
references.citation: Arch Gen Psychiatry. 1961 Jun;4:561-71
references.pmid: 13688369
references.citation: Pharmacoeconomics. 2006;24(11):1069-78
references.pmid: 17067192
references.citation: Ann Neurol. 2001 Mar;49(3):298-303
references.pmid: 11261503
references.citation: Lancet. 2002 Aug 31;360(9334):711-5
references.pmid: 12241891
references.citation: Arch Neurol. 2004 Jul;61(7):1044-53
references.pmid: 15262734
references.citation: Parkinsonism Relat Disord. 2005 Jun;11(4):221-6
references.pmid: 15878582
references.citation: J Neurol. 1998 May;245 Suppl 1:S10-4
references.pmid: 9617716
references.citation: Pharmacoeconomics. 2003;21(2):115-27
references.pmid: 12515573
references.citation: Qual Life Res. 1995 Jun;4(3):241-8
references.pmid: 7613534
references.citation: Neurology. 1967 May;17(5):427-42
references.pmid: 6067254
references.citation: Pharmacoeconomics. 2001;19(10):1013-38
references.pmid: 11735671
references.citation: Mov Disord. 2003 Jun;18(6):637-45
references.pmid: 12784266
references.citation: Pharmacoeconomics. 2005;23(8):817-36
references.pmid: 16097843
references.citation: Ann Neurol. 1984 Sep;16(3):278-82
references.pmid: 6333204
references.citation: Expert Rev Neurother. 2004 Nov;4(6):985-93
references.pmid: 15853525
references.citation: Pharmacoeconomics. 1998 Sep;14(3):299-312
references.pmid: 10186468
references.citation: Pharmacoeconomics. 2001;19(8):875-86
references.pmid: 11596839
references.citation: Med Decis Making. 2007 May-Jun;27(3):327-34
references.pmid: 17502449
references.citation: Eur J Neurol. 2005 Dec;12(12):956-63
references.pmid: 16324089
references.citation: Parkinsonism Relat Disord. 2003 Jun;9(5):301-7
references.pmid: 12781598
references.citation: Mov Disord. 2007 Jul 30;22(10):1390-1401
references.pmid: 17516489
references.citation: BMJ. 1992 Jul 18;305(6846):160-4
references.pmid: 1285753
references.citation: N Engl J Med. 2007 Jan 4;356(1):29-38
references.pmid: 17202453
references.citation: Ann Neurol. 1986 Apr;19(4):365-72
references.pmid: 3707088
references.citation: Med Decis Making. 2004 Sep-Oct;24(5):472-85
references.pmid: 15358996
references.citation: Nervenarzt. 2006 Oct;77(10):1204-9
references.pmid: 17004081
references.citation: Qual Life Res. 1996 Apr;5(2):195-204
references.pmid: 8998488
references.citation: Neurologia. 1999 Aug-Sep;14(7):338-43
references.pmid: 10570620
references.citation: Stat Methods Med Res. 2002 Dec;11(6):455-68
references.pmid: 12516984
references.citation: Pharmacoeconomics. 2005;23(6):529-36
references.pmid: 15960550
references.citation: Pharmacoeconomics. 2006;24(11):1043-53
references.pmid: 17067190
references.citation: Mov Disord. 2005 Nov;20(11):1449-54
references.pmid: 16007641
references.citation: Health Policy. 1992 Jul;21(3):249-79
references.pmid: 10120196
references.citation: Mov Disord. 1993 Oct;8(4):466-72
references.pmid: 8232356
references.citation: N Engl J Med. 2000 May 18;342(20):1484-91
references.pmid: 10816186
references.citation: Mov Disord. 2003 Dec;18(12):1455-8
references.pmid: 14673881
references.citation: Mov Disord. 2003 Oct;18(10):1139-45
references.pmid: 14534917
references.citation: Drugs. 1998;55 Suppl 1:23-30
references.pmid: 9483167
references.citation: Mov Disord. 2000 May;15(3):439-45
references.pmid: 10830407
references.citation: Mov Disord. 2007 Jan;22(1):41-7
references.pmid: 17115387
references.citation: Mov Disord. 2006 Nov;21(11):1844-50
references.pmid: 16958094
references.citation: Mov Disord. 2002 Jan;17(1):60-7
references.pmid: 11835440
references.citation: N Engl J Med. 1989 Nov 16;321(20):1364-71
references.pmid: 2509910
references.citation: Arch Neurol. 1987 Oct;44(10):1013-6
references.pmid: 3632372
references.citation: Eur J Neurol. 2006 Nov;13(11):1170-85
references.pmid: 17038031
references.citation: J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4
references.pmid: 8676165
references.citation: Clin Neuropharmacol. 1994;17 Suppl 2:S32-44
references.pmid: 9358193
references.citation: Parkinsonism Relat Disord. 2003 Jan;9(3):163-8
references.pmid: 12573872
references.citation: Pharmacoeconomics. 2001;19(7):729-52
references.pmid: 11548910
references.citation: Value Health. 2004 Sep-Oct;7(5):610-26
references.pmid: 15367256
references.citation: Mov Disord. 2006 Mar;21(3):343-53
references.pmid: 16211594
references.citation: N Engl J Med. 2006 Aug 31;355(9):896-908
references.pmid: 16943402
references.citation: Pharmacoeconomics. 2005;23(5):449-59
references.pmid: 15896097
references.citation: Mov Disord. 2003 Aug;18(8):898-905
references.pmid: 12889079
references.citation: Value Health. 2001 Jul-Aug;4(4):308-15
references.pmid: 11705298
references.citation: J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73
references.pmid: 10864606
references.citation: Neuroepidemiology. 2000 Mar-Apr;19(2):100-8
references.pmid: 10686534
references.citation: Pharmacoeconomics. 1998 Nov;14(5):541-57
references.pmid: 10344917
references.citation: Value Health. 2003 Jan-Feb;6(1):9-17
references.pmid: 12535234
references.citation: Mov Disord. 2003 Jul;18(7):773-83
references.pmid: 12815656
references.citation: Neurology. 2002 Jul 9;59(1):103-8
references.pmid: 12105315
references.citation: Health Econ. 1994 Mar-Apr;3(2):95-104
references.pmid: 8044216
references.citation: J Geriatr Psychiatry Neurol. 1992 Jul-Sep;5(3):142-8
references.pmid: 1497791
references.citation: Eur J Health Econ. 2003;4(1):37-42
references.pmid: 15609167
references.citation: Parkinsonism Relat Disord. 2004 Dec;10(8):493-9
references.pmid: 15542010
references.citation: Health Policy. 1990 Dec;16(3):199-208
references.pmid: 10109801
references.citation: Mov Disord. 2004 Sep;19(9):1020-8
references.pmid: 15372591
references.citation: Parkinsonism Relat Disord. 2007 Mar;13(2):108-14
references.pmid: 17055326
references.citation: Pharmacoeconomics. 1999 Jul;16(1):59-69
references.pmid: 10539122
references.citation: Mov Disord. 2002 Nov;17(6):1213-20
references.pmid: 12465059
references.citation: Age Ageing. 1997 Sep;26(5):353-7
references.pmid: 9351479
references.citation: Eur J Health Econ. 2003 Sep;4(3):222-31
references.pmid: 15609189
references.citation: Value Health. 2005 Sep-Oct;8(5):521-33
references.pmid: 16176491
references.citation: Mov Disord. 2002 Sep;17(5):867-76
references.pmid: 12360535
references.citation: Parkinsonism Relat Disord. 2003 Jun;9(5):291-4
references.pmid: 12781596
references.citation: Mov Disord. 2000 Nov;15(6):1112-8
references.pmid: 11104193